Lisinopril

Identification

Name

Lisinopril

Accession Number

DB00722  (APRD00560)

Type

Small Molecule

Groups

Approved, Investigational

Description

Lisinopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Lisinopril may be used to treat hypertension and symptomatic congestive heart failure, to improve survival in certain individuals following myocardial infarction, and to prevent progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for DB00722 (Lisinopril)

×

Close

Synonyms

• (S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
• [N2-[(S)-1-CARBOXY-3-phenylpropyl]-L-lysyl-L-proline
• Lisinopril
• Lisinopril anhydrous
• Lisinoprilum

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Lisinopril dihydrate	E7199S1YWR	83915-83-7	CZRQXSDBMCMPNJ-ZUIPZQNBSA-N

Product Images

PreviousNext

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Act Lisinopril	Tablet	10 mg	Oral	Actavis Pharma Company	2007-10-17	Not applicable
Act Lisinopril	Tablet	5 mg	Oral	Actavis Pharma Company	2007-10-17	Not applicable
Act Lisinopril	Tablet	20 mg	Oral	Actavis Pharma Company	2007-10-17	Not applicable
Lisinopril	Tablet	20 mg	Oral	Cobalt Laboratories	Not applicable	Not applicable
Lisinopril	Tablet	10 mg	Oral	Sorres Pharma Inc	2009-06-22	2014-06-20
Lisinopril	Tablet	40 mg	Oral	Sivem Pharmaceuticals Ulc	Not applicable	Not applicable
Lisinopril	Tablet	5 mg	Oral	Sivem Pharmaceuticals Ulc	2012-06-11	Not applicable
Lisinopril	Tablet	10 mg	Oral	Meliapharm Inc	2008-03-12	2014-06-25
Lisinopril	Tablet	20 mg	Oral	Sivem Pharmaceuticals Ulc	2012-06-11	Not applicable
Lisinopril	Tablet	10 mg	Oral	Cobalt Laboratories	Not applicable	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-lisinopril Tablet (type P) - 10mg	Tablet	10 mg	Oral	Apotex Corporation	1996-10-30	2001-08-02
Apo-lisinopril Tablet (type P) - 20mg	Tablet	20 mg	Oral	Apotex Corporation	1996-10-30	2001-08-02
Apo-lisinopril Tablet (type P) - 40mg	Tablet	40 mg	Oral	Apotex Corporation	1996-12-30	2001-08-02
Apo-lisinopril Tablet (type P) - 5mg	Tablet	5 mg	Oral	Apotex Corporation	1996-10-30	2001-08-02
Apo-lisinopril Tablet 10 mg	Tablet	10 mg	Oral	Apotex Corporation	1996-10-30	Not applicable
Apo-lisinopril Tablet 20 mg	Tablet	20 mg	Oral	Apotex Corporation	1996-10-30	Not applicable
Apo-lisinopril Tablet 40 mg	Tablet	40 mg	Oral	Apotex Corporation	1996-10-30	Not applicable
Apo-lisinopril Tablet 5 mg	Tablet	5 mg	Oral	Apotex Corporation	1996-10-30	Not applicable
Auro-lisinopril	Tablet	5 mg	Oral	Auro Pharma Inc	2013-02-12	Not applicable
Auro-lisinopril	Tablet	20 mg	Oral	Auro Pharma Inc	2013-02-12	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Apo-lisinopril/hctz	Lisinopril (10 mg) + Hydrochlorothiazide (12.5 mg)	Tablet	Oral	Apotex Corporation	2007-09-05	Not applicable
Apo-lisinopril/hctz	Lisinopril (20 mg) + Hydrochlorothiazide (25 mg)	Tablet	Oral	Apotex Corporation	2007-11-21	Not applicable
Apo-lisinopril/hctz	Lisinopril (20 mg) + Hydrochlorothiazide (12.5 mg)	Tablet	Oral	Apotex Corporation	2007-11-21	Not applicable
Ava-lisinopril Hct	Lisinopril (20 mg) + Hydrochlorothiazide (25 mg)	Tablet	Oral	Avanstra Inc	2011-08-18	2014-08-21
Ava-lisinopril Hct	Lisinopril (20 mg) + Hydrochlorothiazide (12.5 mg)	Tablet	Oral	Avanstra Inc	2011-08-18	2014-08-21
Ava-lisinopril Hct	Lisinopril (10 mg) + Hydrochlorothiazide (12.5 mg)	Tablet	Oral	Avanstra Inc	2011-08-18	2014-08-21
Lisinopril and HCTZ	Lisinopril (20 mg/1) + Hydrochlorothiazide (25 mg/1)	Tablet	Oral	Northwind Pharmaceuticals	2014-07-10	Not applicable
Lisinopril and hydrochlorothiazide	Lisinopril (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)	Tablet	Oral	Remedy Repack	2013-07-05	2017-08-10
Lisinopril and Hydrochlorothiazide	Lisinopril (20 mg/1) + Hydrochlorothiazide (12.5 mg/1)	Tablet	Oral	Proficient Rx LP	2006-04-10	Not applicable
Lisinopril and Hydrochlorothiazide	Lisinopril (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)	Tablet	Oral	Aphena Pharma Solutions Tennessee, Inc.	2013-06-18	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Lytensopril	Lisinopril + L-Arginine	Kit		Physician Therapeutics Llc	2011-07-07	Not applicable
Lytensopril-90	Lisinopril + L-Arginine	Kit		Physician Therapeutics Llc	2011-07-07	2016-10-13

International/Other Brands

Acebitor (GlaxoSmithKline) / Acemin (AstraZeneca) / Acerbon (AstraZeneca) / Acinopril (sanofi-aventis) / Bellisin (Ranbaxy) / Biopril (Biochem) / Dapril (Medochemie) / Fibsol (Sigma) / Fisopril (Sanofi-Aventis) / Hipril (Micro Labs) / Linopril (Klinger (Brazil)) / Lisipril (Hexal (Czech Republic), Orion (Finland)) / Noperten (Dexa (Indonesia)) / Presiten (Magnachem) / Ranolip (Ranbaxy) / Ranopril (Ranbaxy) / Rantex (Biotech) / Sinopren (Ranbaxy) / Sinopril (Eczacibasi (Russia)) / Tensopril (Merck)

Categories

• ACE Inhibitors and Calcium Channel Blockers
• ACE Inhibitors and Diuretics
• Agents Acting on the Renin-Angiotensin System
• Agents causing hyperkalemia
• Amino Acids, Peptides, and Proteins
• Angiotensin-Converting Enzyme Inhibitors
• Antihypertensive Agents
• Cardiotonic Agents
• Cardiovascular Agents
• Cardiovascular System
• Dipeptides
• Enzyme Inhibitors
• Hypotensive Agents
• Lipid Modifying Agents
• Oligopeptides
• Peptides
• Protease Inhibitors
• Protective Agents

UNII

7Q3P4BS2FD

CAS number

76547-98-3

Weight

Average: 405.4879
Monoisotopic: 405.226371117

Chemical Formula

C₂₁H₃₁N₃O₅

InChI Key

RLAWWYSOJDYHDC-BZSNNMDCSA-N

InChI

InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1

IUPAC Name

(2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid

SMILES

NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O

Pharmacology

Indication

For the treatment of hypertension and symptomatic congestive heart failure. May be used in conjunction with thrombolytic agents, aspirin and/or β-blockers to improve survival in hemodynamically stable individuals following myocardial infarction. May be used to slow the progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.

Associated Conditions

• Acute Myocardial Infarction (AMI)
• Cardiovascular Events
• Congestive Heart Failure (CHF)
• Diabetic Nephropathies
• High Blood Pressure (Hypertension)
• Migraines

Pharmacodynamics

Lisinopril is an orally active ACE inhibitor that antagonizes the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may further sustain the effects of lisinopril by causing increased vasodilation and decreased blood pressure.

Mechanism of action

There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Lisinopril, one of the few ACE inhibitors that is not a prodrug, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Lisinopril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.

Target	Actions	Organism
AAngiotensin-converting enzyme	inhibitor	Human

Absorption

Approximately 25%, but widely variable between individuals (6 to 60%) in all doses tested (5-80 mg); absorption is unaffected by food

Volume of distribution

Not Available

Protein binding

Lisinopril does not appear to be bound to serum proteins other than ACE.

Metabolism

Does not undergo metabolism, excreted unchanged in urine.

Route of elimination

Lisinopril does not undergo metabolism and is excreted unchanged entirely in the urine.

Half life

Effective half life of accumulation following multiple dosing is 12 hours.

Clearance

• 10 L/h [child weighting 30 kg receiving doses of 0.1 to 0.2 mg/kg]

Toxicity

Symptoms of overdose include severe hypotension, electrolyte disturbances, and renal failure. LD₅₀= 2000 mg/kg(orally in rat). Most frequent adverse effects include headache, dizziness, cough, fatigue and diarrhea.

Affected organisms

• Humans and other mammals

Pathways

Pathway	Category
Lisinopril Action Pathway	Drug action

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
(4R)-limonene	The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Lisinopril.	Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Lisinopril.	Experimental
Abacavir	The serum concentration of Abacavir can be decreased when it is combined with Lisinopril.	Approved, Investigational
Acebutolol	Lisinopril may increase the hypotensive activities of Acebutolol.	Approved, Investigational
Aceclofenac	The risk or severity of adverse effects can be increased when Aceclofenac is combined with Lisinopril.	Approved, Investigational
Acemetacin	The therapeutic efficacy of Lisinopril can be decreased when used in combination with Acemetacin.	Approved, Experimental, Investigational
Acetylsalicylic acid	The therapeutic efficacy of Lisinopril can be decreased when used in combination with Acetylsalicylic acid.	Approved, Vet Approved
Adapalene	The risk or severity of adverse effects can be increased when Adapalene is combined with Lisinopril.	Approved
Alclofenac	The risk or severity of adverse effects can be increased when Alclofenac is combined with Lisinopril.	Approved, Withdrawn
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Lisinopril.	Approved
Alfuzosin	The serum concentration of Alfuzosin can be increased when it is combined with Lisinopril.	Approved, Investigational
Aliskiren	Aliskiren may increase the hypotensive, nephrotoxic, and hyperkalemic activities of Lisinopril.	Approved, Investigational
Allopurinol	The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Lisinopril.	Approved
Alminoprofen	The risk or severity of adverse effects can be increased when Alminoprofen is combined with Lisinopril.	Experimental
Alogliptin	The risk or severity of adverse effects can be increased when Alogliptin is combined with Lisinopril.	Approved
Aloxiprin	The therapeutic efficacy of Lisinopril can be decreased when used in combination with Aloxiprin.	Experimental
Alprazolam	The serum concentration of Alprazolam can be increased when it is combined with Lisinopril.	Approved, Illicit, Investigational
Alprenolol	Lisinopril may increase the hypotensive activities of Alprenolol.	Approved, Withdrawn
Aluminum hydroxide	Aluminum hydroxide can cause a decrease in the absorption of Lisinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Ambrisentan	Lisinopril may increase the hypotensive activities of Ambrisentan.	Approved, Investigational
Ambroxol acefyllinate	The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Lisinopril.	Experimental, Investigational
Amifostine	Lisinopril may increase the hypotensive activities of Amifostine.	Approved, Investigational
Amiloride	Amiloride may increase the hyperkalemic activities of Lisinopril.	Approved
Amineptine	The serum concentration of Amineptine can be increased when it is combined with Lisinopril.	Illicit, Withdrawn
Aminophylline	The serum concentration of Aminophylline can be decreased when it is combined with Lisinopril.	Approved
Aminosalicylic Acid	The therapeutic efficacy of Lisinopril can be decreased when used in combination with Aminosalicylic Acid.	Approved
Amiodarone	The risk or severity of adverse effects can be increased when Amiodarone is combined with Lisinopril.	Approved, Investigational
Amitriptyline	The serum concentration of Amitriptyline can be increased when it is combined with Lisinopril.	Approved
Amitriptylinoxide	The serum concentration of Amitriptylinoxide can be increased when it is combined with Lisinopril.	Approved, Investigational
Amlodipine	Amlodipine may increase the hypotensive activities of Lisinopril.	Approved
Amobarbital	Amobarbital may increase the hypotensive activities of Lisinopril.	Approved, Illicit
Amoxapine	The serum concentration of Amoxapine can be increased when it is combined with Lisinopril.	Approved
Amphetamine	Amphetamine may increase the hypotensive activities of Lisinopril.	Approved, Illicit, Investigational
Amphotericin B	The risk or severity of adverse effects can be increased when Amphotericin B is combined with Lisinopril.	Approved, Investigational
Amyl Nitrite	The risk or severity of adverse effects can be increased when Lisinopril is combined with Amyl Nitrite.	Approved
Andrographolide	The risk or severity of adverse effects can be increased when Andrographolide is combined with Lisinopril.	Investigational
Anisodamine	The risk or severity of adverse effects can be increased when Anisodamine is combined with Lisinopril.	Investigational
Antipyrine	The risk or severity of adverse effects can be increased when Antipyrine is combined with Lisinopril.	Approved, Investigational
Apocynin	The risk or severity of adverse effects can be increased when Apocynin is combined with Lisinopril.	Investigational
Apomorphine	The risk or severity of adverse effects can be increased when Apomorphine is combined with Lisinopril.	Approved, Investigational
Apraclonidine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Apraclonidine.	Approved
Apremilast	The risk or severity of adverse effects can be increased when Apremilast is combined with Lisinopril.	Approved, Investigational
Aprotinin	Aprotinin may decrease the antihypertensive activities of Lisinopril.	Approved, Investigational, Withdrawn
Aripiprazole	Aripiprazole may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Arotinolol	The risk or severity of adverse effects can be increased when Arotinolol is combined with Lisinopril.	Investigational
Arsenic trioxide	The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Lisinopril.	Approved, Investigational
Atenolol	Atenolol may increase the hypotensive activities of Lisinopril.	Approved
Atorvastatin	The risk or severity of adverse effects can be increased when Atorvastatin is combined with Lisinopril.	Approved
Avanafil	Avanafil may increase the antihypertensive activities of Lisinopril.	Approved
Azapropazone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Lisinopril.	Withdrawn
Azathioprine	The risk or severity of anemia and severe leukopenia can be increased when Lisinopril is combined with Azathioprine.	Approved
Azelastine	The risk or severity of adverse effects can be increased when Azelastine is combined with Lisinopril.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lisinopril.	Approved, Investigational
Azosemide	Azosemide may increase the hypotensive activities of Lisinopril.	Investigational
Balsalazide	The risk or severity of adverse effects can be increased when Balsalazide is combined with Lisinopril.	Approved, Investigational
Barbexaclone	Barbexaclone may increase the hypotensive activities of Lisinopril.	Experimental
Barbital	Barbital may increase the hypotensive activities of Lisinopril.	Illicit
Barnidipine	Lisinopril may increase the antihypertensive activities of Barnidipine.	Approved
Benazepril	Benazepril may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Bendazac	The risk or severity of adverse effects can be increased when Bendazac is combined with Lisinopril.	Experimental
Bendroflumethiazide	The risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Lisinopril.	Approved
Benmoxin	Benmoxin may increase the hypotensive activities of Lisinopril.	Withdrawn
Benorilate	The risk or severity of adverse effects can be increased when Benorilate is combined with Lisinopril.	Experimental
Benoxaprofen	The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Lisinopril.	Withdrawn
Benzthiazide	The risk or severity of hypotension can be increased when Benzthiazide is combined with Lisinopril.	Approved
Benzydamine	The risk or severity of adverse effects can be increased when Benzydamine is combined with Lisinopril.	Approved
Bepridil	Lisinopril may increase the hypotensive activities of Bepridil.	Approved, Withdrawn
Betaxolol	Betaxolol may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Bethanidine	Bethanidine may increase the hypotensive activities of Lisinopril.	Approved
Bevonium	The risk or severity of adverse effects can be increased when Bevonium is combined with Lisinopril.	Experimental
Bietaserpine	Bietaserpine may increase the hypotensive activities of Lisinopril.	Experimental
Bimatoprost	Lisinopril may increase the hypotensive activities of Bimatoprost.	Approved, Investigational
Bisoprolol	Bisoprolol may increase the hypotensive activities of Lisinopril.	Approved
Boceprevir	The serum concentration of Lisinopril can be decreased when it is combined with Boceprevir.	Approved, Withdrawn
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Lisinopril.	Approved, Investigational
Bosentan	Bosentan may increase the hypotensive activities of Lisinopril.	Approved, Investigational
BQ-123	Lisinopril may increase the hypotensive activities of BQ-123.	Investigational
Bretylium	Lisinopril may increase the hypotensive activities of Bretylium.	Approved
Brimonidine	Brimonidine may increase the antihypertensive activities of Lisinopril.	Approved
Brofaromine	Brofaromine may increase the hypotensive activities of Lisinopril.	Experimental
Bromfenac	The risk or severity of adverse effects can be increased when Bromfenac is combined with Lisinopril.	Approved
Bromocriptine	The serum concentration of Bromocriptine can be increased when it is combined with Lisinopril.	Approved, Investigational
Bucillamine	The risk or severity of adverse effects can be increased when Bucillamine is combined with Lisinopril.	Investigational
Bufexamac	The risk or severity of adverse effects can be increased when Bufexamac is combined with Lisinopril.	Approved, Experimental
Bumadizone	The risk or severity of adverse effects can be increased when Bumadizone is combined with Lisinopril.	Experimental
Bumetanide	Bumetanide may increase the hypotensive activities of Lisinopril.	Approved
Bupivacaine	The risk or severity of adverse effects can be increased when Bupivacaine is combined with Lisinopril.	Approved, Investigational
Bupranolol	Lisinopril may increase the hypotensive activities of Bupranolol.	Approved
Butriptyline	The serum concentration of Butriptyline can be increased when it is combined with Lisinopril.	Approved
Cabergoline	The serum concentration of Cabergoline can be increased when it is combined with Lisinopril.	Approved
Cadralazine	Cadralazine may increase the hypotensive activities of Lisinopril.	Experimental
Cafedrine	Lisinopril may increase the hypotensive activities of Cafedrine.	Investigational
Calcium Carbonate	Calcium Carbonate can cause a decrease in the absorption of Lisinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Canagliflozin	The risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Lisinopril.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Candesartan is combined with Lisinopril.	Experimental
Candesartan cilexetil	The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Lisinopril.	Approved
Candoxatril	Candoxatril may increase the hypotensive activities of Lisinopril.	Experimental
Captopril	Lisinopril may increase the hypotensive activities of Captopril.	Approved
Carbaspirin calcium	The therapeutic efficacy of Lisinopril can be decreased when used in combination with Carbaspirin calcium.	Experimental, Investigational
Carbetocin	The risk or severity of adverse effects can be increased when Carbetocin is combined with Lisinopril.	Approved, Investigational
Caroxazone	Caroxazone may increase the hypotensive activities of Lisinopril.	Withdrawn
Carprofen	The risk or severity of adverse effects can be increased when Carprofen is combined with Lisinopril.	Approved, Vet Approved, Withdrawn
Carvedilol	Lisinopril may increase the hypotensive activities of Carvedilol.	Approved, Investigational
Castanospermine	The risk or severity of adverse effects can be increased when Castanospermine is combined with Lisinopril.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Celecoxib is combined with Lisinopril.	Approved, Investigational
Celiprolol	Lisinopril may increase the hypotensive activities of Celiprolol.	Approved, Investigational
Chloroquine	The risk or severity of adverse effects can be increased when Chloroquine is combined with Lisinopril.	Approved, Investigational, Vet Approved
Chlorothiazide	The risk or severity of hypotension can be increased when Chlorothiazide is combined with Lisinopril.	Approved, Vet Approved
Chlorpromazine	The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lisinopril.	Approved, Investigational, Vet Approved
Chlorthalidone	The risk or severity of hypotension can be increased when Chlorthalidone is combined with Lisinopril.	Approved
Choline magnesium trisalicylate	The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Lisinopril.	Approved
Cicletanine	Lisinopril may increase the hypotensive activities of Cicletanine.	Investigational
Cilazapril	Lisinopril may increase the hypotensive activities of Cilazapril.	Approved
Cilnidipine	The risk or severity of adverse effects can be increased when Cilnidipine is combined with Lisinopril.	Approved, Investigational
Ciprofloxacin	The risk or severity of hyperkalemia can be increased when Lisinopril is combined with Ciprofloxacin.	Approved, Investigational
Clarithromycin	The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Lisinopril.	Approved
Clevidipine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Clevidipine.	Approved, Investigational
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Lisinopril.	Approved, Investigational
Clomipramine	The serum concentration of Clomipramine can be increased when it is combined with Lisinopril.	Approved, Investigational, Vet Approved
Clonidine	Clonidine may increase the hypotensive activities of Lisinopril.	Approved
Clonixin	The risk or severity of adverse effects can be increased when Clonixin is combined with Lisinopril.	Approved
Cloranolol	Lisinopril may increase the hypotensive activities of Cloranolol.	Experimental
Clozapine	The risk or severity of adverse effects can be increased when Clozapine is combined with Lisinopril.	Approved
Conivaptan	The risk or severity of adverse effects can be increased when Conivaptan is combined with Lisinopril.	Approved, Investigational
Cryptenamine	Lisinopril may increase the hypotensive activities of Cryptenamine.	Approved
Curcumin	The risk or severity of adverse effects can be increased when Curcumin is combined with Lisinopril.	Approved, Investigational
Cyclopenthiazide	The risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Lisinopril.	Experimental
Cyclophosphamide	The risk or severity of adverse effects can be increased when Lisinopril is combined with Cyclophosphamide.	Approved, Investigational
Cyclosporine	The risk or severity of hyperkalemia can be increased when Lisinopril is combined with Cyclosporine.	Approved, Investigational, Vet Approved
Dapagliflozin	The risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Lisinopril.	Approved
Dapoxetine	Dapoxetine may increase the orthostatic hypotensive activities of Lisinopril.	Investigational
Debrisoquin	Debrisoquin may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Delapril	Lisinopril may increase the hypotensive activities of Delapril.	Investigational
Delavirdine	The serum concentration of Delavirdine can be decreased when it is combined with Lisinopril.	Approved
Dersalazine	The therapeutic efficacy of Lisinopril can be decreased when used in combination with Dersalazine.	Investigational
Deserpidine	Lisinopril may increase the hypotensive activities of Deserpidine.	Approved
Desflurane	The risk or severity of adverse effects can be increased when Desflurane is combined with Lisinopril.	Approved
Desipramine	The serum concentration of Desipramine can be increased when it is combined with Lisinopril.	Approved, Investigational
Dexmedetomidine	The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lisinopril.	Approved, Vet Approved
Dexniguldipine	Lisinopril may increase the hypotensive activities of Dexniguldipine.	Experimental
Diazoxide	Diazoxide may increase the hypotensive activities of Lisinopril.	Approved
Dibenzepin	The serum concentration of Dibenzepin can be increased when it is combined with Lisinopril.	Experimental
Diclofenac	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diclofenac is combined with Lisinopril.	Approved, Vet Approved
Diclofenamide	The risk or severity of adverse effects can be increased when Lisinopril is combined with Diclofenamide.	Approved, Investigational
Diethylnorspermine	Lisinopril may increase the hypotensive activities of Diethylnorspermine.	Investigational
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be decreased when it is combined with Lisinopril.	Approved, Investigational
Difenpiramide	The risk or severity of adverse effects can be increased when Difenpiramide is combined with Lisinopril.	Experimental
Diflunisal	The therapeutic efficacy of Lisinopril can be decreased when used in combination with Diflunisal.	Approved, Investigational
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Lisinopril.	Approved
Dihydralazine	Dihydralazine may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Dihydroergotamine	The serum concentration of Dihydroergotamine can be increased when it is combined with Lisinopril.	Approved, Investigational
Diltiazem	Diltiazem may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Dimetacrine	The serum concentration of Dimetacrine can be increased when it is combined with Lisinopril.	Approved, Withdrawn
Dinutuximab	The risk or severity of adverse effects can be increased when Lisinopril is combined with Dinutuximab.	Approved, Investigational
Dipyridamole	The risk or severity of adverse effects can be increased when Lisinopril is combined with Dipyridamole.	Approved
Dorzolamide	Lisinopril may increase the hypotensive activities of Dorzolamide.	Approved
Dosulepin	The serum concentration of Dosulepin can be increased when it is combined with Lisinopril.	Approved
Doxazosin	Doxazosin may increase the hypotensive activities of Lisinopril.	Approved
Doxepin	The serum concentration of Doxepin can be increased when it is combined with Lisinopril.	Approved, Investigational
Drospirenone	Lisinopril may increase the hyperkalemic activities of Drospirenone.	Approved
Droxicam	The risk or severity of adverse effects can be increased when Droxicam is combined with Lisinopril.	Withdrawn
Duloxetine	Lisinopril may increase the orthostatic hypotensive activities of Duloxetine.	Approved
Duvelisib	The risk or severity of adverse effects can be increased when Duvelisib is combined with Lisinopril.	Investigational
Dyphylline	The serum concentration of Dyphylline can be decreased when it is combined with Lisinopril.	Approved
E-6201	The risk or severity of adverse effects can be increased when E-6201 is combined with Lisinopril.	Investigational
Efonidipine	Lisinopril may increase the hypotensive activities of Efonidipine.	Approved, Investigational
Empagliflozin	The risk or severity of adverse effects can be increased when Lisinopril is combined with Empagliflozin.	Approved
Enalaprilat	Lisinopril may increase the hypotensive activities of Enalaprilat.	Approved
Endralazine	Endralazine may increase the hypotensive activities of Lisinopril.	Experimental
Enfuvirtide	The serum concentration of Enfuvirtide can be increased when it is combined with Lisinopril.	Approved, Investigational
Epanolol	Lisinopril may increase the hypotensive activities of Epanolol.	Experimental
Epirizole	The risk or severity of adverse effects can be increased when Epirizole is combined with Lisinopril.	Approved
Epitizide	The risk or severity of hypotension can be increased when Epitizide is combined with Lisinopril.	Experimental
Eplerenone	Eplerenone may increase the hyperkalemic activities of Lisinopril.	Approved
Epoprostenol	Lisinopril may increase the hypotensive activities of Epoprostenol.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Eprosartan is combined with Lisinopril.	Approved
Ergoloid mesylate	The serum concentration of Ergoloid mesylate can be increased when it is combined with Lisinopril.	Approved
Ergonovine	The serum concentration of Ergonovine can be increased when it is combined with Lisinopril.	Approved
Ergotamine	The serum concentration of Ergotamine can be increased when it is combined with Lisinopril.	Approved
Esmolol	The risk or severity of adverse effects can be increased when Esmolol is combined with Lisinopril.	Approved
Estradiol cypionate	The serum concentration of Estradiol cypionate can be decreased when it is combined with Lisinopril.	Approved, Investigational, Vet Approved
Estradiol valerate	The serum concentration of Estradiol valerate can be decreased when it is combined with Lisinopril.	Approved, Investigational, Vet Approved
Etacrynic acid	Etacrynic acid may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Lisinopril.	Approved, Investigational
Ethenzamide	The risk or severity of adverse effects can be increased when Ethenzamide is combined with Lisinopril.	Experimental
Etodolac	The risk or severity of adverse effects can be increased when Etodolac is combined with Lisinopril.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of adverse effects can be increased when Etofenamate is combined with Lisinopril.	Approved, Investigational
Etoricoxib	The risk or severity of adverse effects can be increased when Etoricoxib is combined with Lisinopril.	Approved, Investigational
Etravirine	The serum concentration of Etravirine can be decreased when it is combined with Lisinopril.	Approved
Evening primrose oil	The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Lisinopril.	Investigational, Nutraceutical
Everolimus	The risk or severity of adverse effects can be increased when Everolimus is combined with Lisinopril.	Approved
Exisulind	The risk or severity of adverse effects can be increased when Exisulind is combined with Lisinopril.	Investigational
Felbinac	The risk or severity of adverse effects can be increased when Felbinac is combined with Lisinopril.	Experimental
Felodipine	Lisinopril may increase the hypotensive activities of Felodipine.	Approved, Investigational
Fenbufen	The risk or severity of adverse effects can be increased when Fenbufen is combined with Lisinopril.	Approved
Fenoldopam	Lisinopril may increase the hypotensive activities of Fenoldopam.	Approved
Fenoprofen	The risk or severity of adverse effects can be increased when Fenoprofen is combined with Lisinopril.	Approved
Fentiazac	The risk or severity of adverse effects can be increased when Fentiazac is combined with Lisinopril.	Experimental
Feprazone	The risk or severity of adverse effects can be increased when Feprazone is combined with Lisinopril.	Experimental
Ferulic acid	Lisinopril may increase the hypotensive activities of Ferulic acid.	Experimental
Fimasartan	The risk or severity of adverse effects can be increased when Fimasartan is combined with Lisinopril.	Approved, Investigational
Floctafenine	The risk or severity of adverse effects can be increased when Floctafenine is combined with Lisinopril.	Approved, Withdrawn
Flunixin	The risk or severity of adverse effects can be increased when Flunixin is combined with Lisinopril.	Vet Approved
Flunoxaprofen	The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Lisinopril.	Experimental
Flurbiprofen	The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Lisinopril.	Approved, Investigational
Forasartan	The risk or severity of adverse effects can be increased when Forasartan is combined with Lisinopril.	Experimental
Fosinopril	Fosinopril may increase the hypotensive activities of Lisinopril.	Approved
Fostamatinib	Fostamatinib may increase the antihypertensive activities of Lisinopril.	Approved, Investigational
Furazolidone	Furazolidone may increase the hypotensive activities of Lisinopril.	Approved, Investigational, Vet Approved
Furosemide	Furosemide may increase the hypotensive activities of Lisinopril.	Approved, Vet Approved
Garlic	The serum concentration of Lisinopril can be decreased when it is combined with Garlic.	Approved, Nutraceutical
Guacetisal	The therapeutic efficacy of Lisinopril can be decreased when used in combination with Guacetisal.	Experimental
Guanabenz	Guanabenz may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Guanadrel	Guanadrel may increase the hypotensive activities of Lisinopril.	Approved
Guanazodine	Lisinopril may increase the hypotensive activities of Guanazodine.	Experimental
Guanethidine	Lisinopril may increase the hypotensive activities of Guanethidine.	Approved
Guanfacine	Guanfacine may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Guanoclor	Lisinopril may increase the hypotensive activities of Guanoclor.	Experimental
Guanoxabenz	Lisinopril may increase the hypotensive activities of Guanoxabenz.	Experimental
Guanoxan	Lisinopril may increase the hypotensive activities of Guanoxan.	Experimental
Halothane	The risk or severity of adverse effects can be increased when Halothane is combined with Lisinopril.	Approved, Vet Approved
Harmaline	Harmaline may increase the hypotensive activities of Lisinopril.	Experimental
Hemoglobin crosfumaril	The therapeutic efficacy of Lisinopril can be decreased when used in combination with Hemoglobin crosfumaril.	Experimental
Heparin	The risk or severity of hyperkalemia can be increased when Lisinopril is combined with Heparin.	Approved, Investigational
Hexamethonium	Lisinopril may increase the hypotensive activities of Hexamethonium.	Experimental
Hexobarbital	Hexobarbital may increase the hypotensive activities of Lisinopril.	Approved
Higenamine	The risk or severity of adverse effects can be increased when Higenamine is combined with Lisinopril.	Investigational
Hydralazine	Hydralazine may increase the hypotensive activities of Lisinopril.	Approved
Hydrochlorothiazide	The risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Lisinopril.	Approved, Vet Approved
Hydroflumethiazide	The risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Lisinopril.	Approved, Investigational
Ibuprofen	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Lisinopril.	Approved
Ibuproxam	The risk or severity of adverse effects can be increased when Ibuproxam is combined with Lisinopril.	Withdrawn
Icatibant	Icatibant may decrease the antihypertensive activities of Lisinopril.	Approved, Investigational
Iloprost	The risk or severity of adverse effects can be increased when Iloprost is combined with Lisinopril.	Approved, Investigational
Imidapril	Lisinopril may increase the hypotensive activities of Imidapril.	Investigational
Imidazole salicylate	The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Lisinopril.	Experimental
Imipramine	The serum concentration of Imipramine can be increased when it is combined with Lisinopril.	Approved
Indapamide	The risk or severity of hypotension can be increased when Indapamide is combined with Lisinopril.	Approved
Indenolol	Lisinopril may increase the hypotensive activities of Indenolol.	Withdrawn
Indobufen	The risk or severity of adverse effects can be increased when Indobufen is combined with Lisinopril.	Investigational
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Lisinopril.	Approved, Investigational
Indoprofen	The risk or severity of adverse effects can be increased when Indoprofen is combined with Lisinopril.	Withdrawn
Indoramin	Indoramin may increase the hypotensive activities of Lisinopril.	Withdrawn
Iprindole	The serum concentration of Iprindole can be increased when it is combined with Lisinopril.	Experimental
Iproclozide	Iproclozide may increase the hypotensive activities of Lisinopril.	Withdrawn
Iproniazid	Iproniazid may increase the hypotensive activities of Lisinopril.	Withdrawn
Irbesartan	The risk or severity of adverse effects can be increased when Irbesartan is combined with Lisinopril.	Approved, Investigational
Iron	Iron can cause a decrease in the absorption of Lisinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Iron Dextran	The risk or severity of adverse effects can be increased when Lisinopril is combined with Iron Dextran.	Approved, Vet Approved
Isocarboxazid	Isocarboxazid may increase the hypotensive activities of Lisinopril.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Isoflurane is combined with Lisinopril.	Approved, Vet Approved
Isosorbide Dinitrate	The risk or severity of adverse effects can be increased when Lisinopril is combined with Isosorbide Dinitrate.	Approved, Investigational
Isosorbide Mononitrate	The risk or severity of adverse effects can be increased when Lisinopril is combined with Isosorbide Mononitrate.	Approved
Isoxicam	The risk or severity of adverse effects can be increased when Isoxicam is combined with Lisinopril.	Withdrawn
Isoxsuprine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Isoxsuprine.	Approved, Withdrawn
Isradipine	Isradipine may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Kebuzone	The risk or severity of adverse effects can be increased when Kebuzone is combined with Lisinopril.	Experimental
Ketanserin	Ketanserin may increase the hypotensive activities of Lisinopril.	Investigational
Ketoprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Lisinopril.	Approved, Vet Approved
Ketorolac	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketorolac is combined with Lisinopril.	Approved
Labetalol	Labetalol may increase the hypotensive activities of Lisinopril.	Approved
Lacidipine	Lisinopril may increase the hypotensive activities of Lacidipine.	Approved, Investigational
Lanthanum carbonate	The serum concentration of Lisinopril can be decreased when it is combined with Lanthanum carbonate.	Approved
Latanoprost	Latanoprost may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Leflunomide	The risk or severity of adverse effects can be increased when Leflunomide is combined with Lisinopril.	Approved, Investigational
Lercanidipine	Lercanidipine may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Levobunolol	The risk or severity of adverse effects can be increased when Lisinopril is combined with Levobunolol.	Approved
Levobupivacaine	The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Lisinopril.	Approved, Investigational
Levodopa	Lisinopril may increase the orthostatic hypotensive activities of Levodopa.	Approved
Levosimendan	The risk or severity of adverse effects can be increased when Levosimendan is combined with Lisinopril.	Approved, Investigational
Linagliptin	The risk or severity of adverse effects can be increased when Linagliptin is combined with Lisinopril.	Approved
Linsidomine	Lisinopril may increase the hypotensive activities of Linsidomine.	Experimental
Lisofylline	The risk or severity of adverse effects can be increased when Lisofylline is combined with Lisinopril.	Investigational
Lithium cation	The serum concentration of Lithium can be increased when it is combined with Lisinopril.	Experimental
Lofepramine	The serum concentration of Lofepramine can be increased when it is combined with Lisinopril.	Experimental
Lofexidine	Lisinopril may increase the hypotensive activities of Lofexidine.	Approved, Investigational
Lonazolac	The risk or severity of adverse effects can be increased when Lonazolac is combined with Lisinopril.	Experimental
Lornoxicam	The risk or severity of adverse effects can be increased when Lornoxicam is combined with Lisinopril.	Approved, Investigational
Losartan	The risk or severity of adverse effects can be increased when Losartan is combined with Lisinopril.	Approved
Lovastatin	The serum concentration of Lovastatin can be increased when it is combined with Lisinopril.	Approved, Investigational
Loxoprofen	The risk or severity of adverse effects can be increased when Loxoprofen is combined with Lisinopril.	Approved, Investigational
Lumiracoxib	The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Lisinopril.	Approved, Investigational
Macitentan	Lisinopril may increase the hypotensive activities of Macitentan.	Approved
Magnesium carbonate	Magnesium carbonate can cause a decrease in the absorption of Lisinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Magnesium hydroxide	Magnesium hydroxide can cause a decrease in the absorption of Lisinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Magnesium salicylate	The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Lisinopril.	Approved
Magnesium Trisilicate	Magnesium Trisilicate can cause a decrease in the absorption of Lisinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Manidipine	Lisinopril may increase the hypotensive activities of Manidipine.	Approved, Investigational
Mannitol	The risk or severity of adverse effects can be increased when Lisinopril is combined with Mannitol.	Approved, Investigational
Masoprocol	The risk or severity of adverse effects can be increased when Masoprocol is combined with Lisinopril.	Approved, Investigational
Mebanazine	Mebanazine may increase the hypotensive activities of Lisinopril.	Withdrawn
Mecamylamine	Mecamylamine may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Meclofenamic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lisinopril.	Approved, Vet Approved
Mefenamic acid	The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Lisinopril.	Approved
Melitracen	The serum concentration of Melitracen can be increased when it is combined with Lisinopril.	Experimental, Investigational
Meloxicam	The risk or severity of adverse effects can be increased when Meloxicam is combined with Lisinopril.	Approved, Vet Approved
Mesalazine	The therapeutic efficacy of Lisinopril can be decreased when used in combination with Mesalazine.	Approved
Mestranol	The serum concentration of Mestranol can be decreased when it is combined with Lisinopril.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with Lisinopril.	Approved, Investigational, Withdrawn
Methazolamide	The risk or severity of adverse effects can be increased when Methazolamide is combined with Lisinopril.	Approved
Methohexital	Methohexital may increase the hypotensive activities of Lisinopril.	Approved
Methoserpidine	Lisinopril may increase the hypotensive activities of Methoserpidine.	Experimental
Methyclothiazide	The risk or severity of hypotension can be increased when Methyclothiazide is combined with Lisinopril.	Approved
Methyl salicylate	The risk or severity of renal failure can be increased when Methyl salicylate is combined with Lisinopril.	Approved, Vet Approved
Methyldopa	Lisinopril may increase the hypotensive activities of Methyldopa.	Approved
Methylene blue	Methylene blue may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Methylergometrine	The serum concentration of Methylergometrine can be increased when it is combined with Lisinopril.	Approved
Methylphenidate	Methylphenidate may decrease the antihypertensive activities of Lisinopril.	Approved, Investigational
Methylphenobarbital	Methylphenobarbital may increase the hypotensive activities of Lisinopril.	Approved
Metipranolol	Lisinopril may increase the hypotensive activities of Metipranolol.	Approved
Metolazone	The risk or severity of hypotension can be increased when Metolazone is combined with Lisinopril.	Approved
Metoprolol	Metoprolol may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Metyrosine	Lisinopril may increase the hypotensive activities of Metyrosine.	Approved
Mibefradil	Lisinopril may increase the hypotensive activities of Mibefradil.	Investigational, Withdrawn
Midazolam	The serum concentration of Midazolam can be increased when it is combined with Lisinopril.	Approved, Illicit
Minaprine	Minaprine may increase the hypotensive activities of Lisinopril.	Approved
Minoxidil	Minoxidil may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Mirodenafil	Mirodenafil may increase the antihypertensive activities of Lisinopril.	Investigational
Mizoribine	The risk or severity of adverse effects can be increased when Mizoribine is combined with Lisinopril.	Investigational
Moclobemide	Moclobemide may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Moexipril	Moexipril may increase the hypotensive activities of Lisinopril.	Approved
Mofebutazone	The risk or severity of adverse effects can be increased when Mofebutazone is combined with Lisinopril.	Experimental
Molsidomine	Molsidomine may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Lisinopril.	Approved, Investigational
Moxonidine	Moxonidine may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Muzolimine	Lisinopril may increase the hypotensive activities of Muzolimine.	Experimental
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Lisinopril.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lisinopril.	Approved
Nabilone	The risk or severity of adverse effects can be increased when Nabilone is combined with Lisinopril.	Approved, Investigational
Nabumetone	The risk or severity of adverse effects can be increased when Nabumetone is combined with Lisinopril.	Approved
Nadolol	Lisinopril may increase the hypotensive activities of Nadolol.	Approved
Nafamostat	The risk or severity of adverse effects can be increased when Nafamostat is combined with Lisinopril.	Approved, Investigational
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with Lisinopril.	Approved
Naftopidil	Lisinopril may increase the hypotensive activities of Naftopidil.	Investigational
Naproxen	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Lisinopril.	Approved, Vet Approved
Nebivolol	Lisinopril may increase the hypotensive activities of Nebivolol.	Approved, Investigational
Nefazodone	The serum concentration of Nefazodone can be increased when it is combined with Lisinopril.	Approved, Withdrawn
Nepafenac	The risk or severity of adverse effects can be increased when Nepafenac is combined with Lisinopril.	Approved, Investigational
Nesiritide	The risk or severity of adverse effects can be increased when Lisinopril is combined with Nesiritide.	Approved, Investigational
Nialamide	Nialamide may increase the hypotensive activities of Lisinopril.	Withdrawn
Nicardipine	Nicardipine may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Nicorandil	Nicorandil may increase the vasodilatory activities of Lisinopril.	Approved, Investigational
Nifedipine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Nifedipine.	Approved
Nifenazone	The risk or severity of adverse effects can be increased when Nifenazone is combined with Lisinopril.	Experimental
Niflumic Acid	The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Lisinopril.	Approved
Niguldipine	Lisinopril may increase the hypotensive activities of Niguldipine.	Experimental
Nilvadipine	Lisinopril may increase the hypotensive activities of Nilvadipine.	Approved, Investigational
Nimesulide	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Lisinopril.	Approved, Investigational, Withdrawn
Nimodipine	Nimodipine may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Nisoldipine	Nisoldipine may increase the hypotensive activities of Lisinopril.	Approved
Nitrendipine	Lisinopril may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Nitric Oxide	The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Lisinopril.	Approved
Nitroaspirin	The therapeutic efficacy of Lisinopril can be decreased when used in combination with Nitroaspirin.	Investigational
Nitroglycerin	The risk or severity of adverse effects can be increased when Lisinopril is combined with Nitroglycerin.	Approved, Investigational
Nitroprusside	Nitroprusside may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Nitrous acid	The risk or severity of adverse effects can be increased when Nitrous acid is combined with Lisinopril.	Approved, Investigational
Nortriptyline	The serum concentration of Nortriptyline can be increased when it is combined with Lisinopril.	Approved
Obinutuzumab	Lisinopril may increase the hypotensive activities of Obinutuzumab.	Approved, Investigational
Octamoxin	Octamoxin may increase the hypotensive activities of Lisinopril.	Withdrawn
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Lisinopril.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Olopatadine is combined with Lisinopril.	Approved
Olsalazine	The risk or severity of adverse effects can be increased when Olsalazine is combined with Lisinopril.	Approved
Omapatrilat	Lisinopril may increase the hypotensive activities of Omapatrilat.	Investigational
Omeprazole	Omeprazole can cause a decrease in the absorption of Lisinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational, Vet Approved
Opipramol	The serum concentration of Opipramol can be increased when it is combined with Lisinopril.	Investigational
Orgotein	The risk or severity of adverse effects can be increased when Orgotein is combined with Lisinopril.	Vet Approved
Oxaprozin	The risk or severity of adverse effects can be increased when Oxaprozin is combined with Lisinopril.	Approved
Oxprenolol	Lisinopril may increase the hypotensive activities of Oxprenolol.	Approved
Oxyphenbutazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lisinopril.	Approved, Withdrawn
Paclitaxel	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Lisinopril.	Approved, Vet Approved
Palmidrol	The risk or severity of adverse effects can be increased when Palmidrol is combined with Lisinopril.	Experimental, Nutraceutical
Papaverine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Papaverine.	Approved, Investigational
Parecoxib	The risk or severity of adverse effects can be increased when Parecoxib is combined with Lisinopril.	Approved
Pargyline	Pargyline may increase the hypotensive activities of Lisinopril.	Approved
Parthenolide	The risk or severity of adverse effects can be increased when Parthenolide is combined with Lisinopril.	Approved, Investigational
Patent Blue	The therapeutic efficacy of Lisinopril can be decreased when used in combination with Patent Blue.	Approved
Penbutolol	Lisinopril may increase the hypotensive activities of Penbutolol.	Approved, Investigational
Pentobarbital	Pentobarbital may increase the hypotensive activities of Lisinopril.	Approved, Investigational, Vet Approved
Pentolinium	Lisinopril may increase the hypotensive activities of Pentolinium.	Approved
Pentoxifylline	Pentoxifylline may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Perindopril	Lisinopril may increase the hypotensive activities of Perindopril.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Pethidine.	Approved
Phenelzine	Phenelzine may increase the hypotensive activities of Lisinopril.	Approved
Pheniprazine	Pheniprazine may increase the hypotensive activities of Lisinopril.	Withdrawn
Phenobarbital	Phenobarbital may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Phenoxybenzamine	Lisinopril may increase the hypotensive activities of Phenoxybenzamine.	Approved
Phenoxypropazine	Phenoxypropazine may increase the hypotensive activities of Lisinopril.	Withdrawn
Phentolamine	Phentolamine may increase the hypotensive activities of Lisinopril.	Approved
Phenyl aminosalicylate	The therapeutic efficacy of Lisinopril can be decreased when used in combination with Phenyl aminosalicylate.	Approved
Phenylbutazone	The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Lisinopril.	Approved, Vet Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lisinopril.	Approved, Investigational
Pinacidil	Pinacidil may increase the hypotensive activities of Lisinopril.	Approved
Pindolol	Lisinopril may increase the hypotensive activities of Pindolol.	Approved, Investigational
Pipamperone	The risk or severity of adverse effects can be increased when Pipamperone is combined with Lisinopril.	Approved, Investigational
Piretanide	Piretanide may increase the hypotensive activities of Lisinopril.	Approved
Pirfenidone	The risk or severity of adverse effects can be increased when Pirfenidone is combined with Lisinopril.	Approved, Investigational
Pirlindole	Pirlindole may increase the hypotensive activities of Lisinopril.	Approved
Piroxicam	The risk or severity of adverse effects can be increased when Piroxicam is combined with Lisinopril.	Approved, Investigational
Pirprofen	The risk or severity of adverse effects can be increased when Pirprofen is combined with Lisinopril.	Experimental
Pivhydrazine	Pivhydrazine may increase the hypotensive activities of Lisinopril.	Withdrawn
Platelet Activating Factor	Lisinopril may increase the hypotensive activities of Platelet Activating Factor.	Experimental
Polythiazide	The risk or severity of hypotension can be increased when Polythiazide is combined with Lisinopril.	Approved
Potassium bicarbonate	Potassium bicarbonate may increase the hyperkalemic activities of Lisinopril.	Approved
Potassium cation	Potassium may increase the hyperkalemic activities of Lisinopril.	Approved, Investigational
Potassium Chloride	The risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Lisinopril.	Approved, Withdrawn
Potassium Citrate	Potassium Citrate may increase the hyperkalemic activities of Lisinopril.	Approved, Investigational, Vet Approved
Pramipexole	The risk or severity of adverse effects can be increased when Pramipexole is combined with Lisinopril.	Approved, Investigational
Pranoprofen	The risk or severity of adverse effects can be increased when Pranoprofen is combined with Lisinopril.	Experimental, Investigational
Prazosin	Prazosin may increase the hypotensive activities of Lisinopril.	Approved
Pregabalin	The risk or severity of angioedema can be increased when Lisinopril is combined with Pregabalin.	Approved, Illicit, Investigational
Primidone	Primidone may increase the hypotensive activities of Lisinopril.	Approved, Vet Approved
Procaine	Procaine may increase the hypotensive activities of Lisinopril.	Approved, Investigational, Vet Approved
Procarbazine	Procarbazine may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Proglumetacin	The risk or severity of adverse effects can be increased when Proglumetacin is combined with Lisinopril.	Experimental
Propacetamol	The risk or severity of adverse effects can be increased when Propacetamol is combined with Lisinopril.	Approved, Investigational
Propafenone	The risk or severity of hyperkalemia can be increased when Lisinopril is combined with Propafenone.	Approved
Propofol	The risk or severity of adverse effects can be increased when Propofol is combined with Lisinopril.	Approved, Investigational, Vet Approved
Propranolol	Lisinopril may increase the hypotensive activities of Propranolol.	Approved, Investigational
Propyphenazone	The risk or severity of adverse effects can be increased when Propyphenazone is combined with Lisinopril.	Experimental
Proquazone	The risk or severity of adverse effects can be increased when Proquazone is combined with Lisinopril.	Experimental
Protriptyline	The serum concentration of Protriptyline can be increased when it is combined with Lisinopril.	Approved
PTC299	The risk or severity of adverse effects can be increased when PTC299 is combined with Lisinopril.	Investigational
Quetiapine	The risk or severity of adverse effects can be increased when Lisinopril is combined with Quetiapine.	Approved
Quinapril	Lisinopril may increase the hypotensive activities of Quinapril.	Approved, Investigational
Quinethazone	The risk or severity of hypotension can be increased when Quinethazone is combined with Lisinopril.	Approved
Quinine	Quinine may increase the hypotensive activities of Lisinopril.	Approved
Ramipril	Ramipril may increase the hypotensive activities of Lisinopril.	Approved
Rasagiline	Rasagiline may increase the hypotensive activities of Lisinopril.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Lisinopril.	Approved
Remikiren	Remikiren may increase the hypotensive activities of Lisinopril.	Approved
Rescinnamine	Lisinopril may increase the hypotensive activities of Rescinnamine.	Approved
Reserpine	Reserpine may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Resveratrol	The risk or severity of adverse effects can be increased when Resveratrol is combined with Lisinopril.	Approved, Experimental, Investigational
Rilmenidine	Rilmenidine may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Riociguat	The serum concentration of Riociguat can be increased when it is combined with Lisinopril.	Approved
Risperidone	Lisinopril may increase the hypotensive activities of Risperidone.	Approved, Investigational
Rituximab	Lisinopril may increase the hypotensive activities of Rituximab.	Approved
Rofecoxib	The risk or severity of adverse effects can be increased when Rofecoxib is combined with Lisinopril.	Approved, Investigational, Withdrawn
Ropinirole	The risk or severity of adverse effects can be increased when Ropinirole is combined with Lisinopril.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Ropivacaine is combined with Lisinopril.	Approved
Rotigotine	The risk or severity of adverse effects can be increased when Rotigotine is combined with Lisinopril.	Approved
Sacubitril	The risk or severity of angioedema can be increased when Lisinopril is combined with Sacubitril.	Approved
Salicylamide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Lisinopril.	Approved
Salicylic acid	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylic acid is combined with Lisinopril.	Approved, Investigational, Vet Approved
Salsalate	The risk or severity of adverse effects can be increased when Salsalate is combined with Lisinopril.	Approved
Saprisartan	The risk or severity of adverse effects can be increased when Saprisartan is combined with Lisinopril.	Experimental
Saralasin	The risk or severity of adverse effects can be increased when Saralasin is combined with Lisinopril.	Investigational
Saxagliptin	The risk or severity of angioedema can be increased when Saxagliptin is combined with Lisinopril.	Approved
Secobarbital	Secobarbital may increase the hypotensive activities of Lisinopril.	Approved, Vet Approved
Selegiline	Selegiline may increase the hypotensive activities of Lisinopril.	Approved, Investigational, Vet Approved
Selexipag	Lisinopril may increase the hypotensive activities of Selexipag.	Approved
Semapimod	The risk or severity of adverse effects can be increased when Semapimod is combined with Lisinopril.	Investigational
Seratrodast	The risk or severity of adverse effects can be increased when Seratrodast is combined with Lisinopril.	Approved
Serrapeptase	The risk or severity of adverse effects can be increased when Serrapeptase is combined with Lisinopril.	Investigational
Sevoflurane	The risk or severity of adverse effects can be increased when Sevoflurane is combined with Lisinopril.	Approved, Vet Approved
Sildenafil	The serum concentration of Sildenafil can be increased when it is combined with Lisinopril.	Approved, Investigational
Simvastatin	The serum concentration of Simvastatin can be increased when it is combined with Lisinopril.	Approved
Sirolimus	The risk or severity of angioedema can be increased when Sirolimus is combined with Lisinopril.	Approved, Investigational
Sitagliptin	The risk or severity of angioedema can be increased when Sitagliptin is combined with Lisinopril.	Approved, Investigational
Sitaxentan	Lisinopril may increase the hypotensive activities of Sitaxentan.	Approved, Investigational, Withdrawn
Sodium aurothiomalate	The risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Lisinopril is combined with Sodium aurothiomalate.	Approved, Investigational
Sodium phosphate, monobasic	The risk or severity of nephrotoxicity can be increased when Lisinopril is combined with Sodium phosphate, monobasic.	Approved
Sotalol	The risk or severity of adverse effects can be increased when Sotalol is combined with Lisinopril.	Approved
Spirapril	Lisinopril may increase the hypotensive activities of Spirapril.	Approved
Spironolactone	The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Lisinopril.	Approved
SRT501	The risk or severity of adverse effects can be increased when SRT501 is combined with Lisinopril.	Investigational
St. John's Wort	The metabolism of Lisinopril can be increased when combined with St. John's Wort.	Approved, Investigational, Nutraceutical
Streptokinase	The risk or severity of adverse effects can be increased when Streptokinase is combined with Lisinopril.	Approved, Investigational
Sufentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Lisinopril.	Approved, Investigational
Sulfasalazine	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Lisinopril.	Approved
Sulindac	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Lisinopril.	Approved, Investigational
Suprofen	The risk or severity of adverse effects can be increased when Suprofen is combined with Lisinopril.	Approved, Withdrawn
Suxibuzone	The risk or severity of adverse effects can be increased when Suxibuzone is combined with Lisinopril.	Experimental
Tacrolimus	The metabolism of Tacrolimus can be decreased when combined with Lisinopril.	Approved, Investigational
Tadalafil	Tadalafil may increase the antihypertensive activities of Lisinopril.	Approved, Investigational
Talinolol	Lisinopril may increase the hypotensive activities of Talinolol.	Investigational
Tamsulosin	The risk or severity of adverse effects can be increased when Tamsulosin is combined with Lisinopril.	Approved, Investigational
Tarenflurbil	The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Lisinopril.	Investigational
Tasosartan	The risk or severity of adverse effects can be increased when Tasosartan is combined with Lisinopril.	Approved
Telmisartan	The risk or severity of adverse effects can be increased when Telmisartan is combined with Lisinopril.	Approved, Investigational
Temocapril	Lisinopril may increase the hypotensive activities of Temocapril.	Experimental, Investigational
Temsirolimus	The risk or severity of adverse effects can be increased when Lisinopril is combined with Temsirolimus.	Approved
Tenidap	The risk or severity of adverse effects can be increased when Tenidap is combined with Lisinopril.	Experimental
Tenoxicam	The risk or severity of adverse effects can be increased when Tenoxicam is combined with Lisinopril.	Approved
Tepoxalin	The risk or severity of adverse effects can be increased when Tepoxalin is combined with Lisinopril.	Vet Approved
Terazosin	The risk or severity of adverse effects can be increased when Lisinopril is combined with Terazosin.	Approved
Teriflunomide	The risk or severity of adverse effects can be increased when Teriflunomide is combined with Lisinopril.	Approved
Terlipressin	Lisinopril may increase the hypotensive activities of Terlipressin.	Approved, Investigational
Tetrahydropalmatine	Lisinopril may increase the hypotensive activities of Tetrahydropalmatine.	Investigational
Thalidomide	The risk or severity of adverse effects can be increased when Thalidomide is combined with Lisinopril.	Approved, Investigational, Withdrawn
Theodrenaline	Lisinopril may increase the hypotensive activities of Theodrenaline.	Investigational
Theophylline	The serum concentration of Theophylline can be decreased when it is combined with Lisinopril.	Approved
Thiamylal	Thiamylal may increase the hypotensive activities of Lisinopril.	Approved, Vet Approved
Thiopental	Thiopental may increase the hypotensive activities of Lisinopril.	Approved, Vet Approved
Thioridazine	The risk or severity of adverse effects can be increased when Thioridazine is combined with Lisinopril.	Approved, Withdrawn
Tianeptine	The serum concentration of Tianeptine can be increased when it is combined with Lisinopril.	Approved, Investigational
Tiaprofenic acid	The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Lisinopril.	Approved
Tibolone	Lisinopril may increase the hypotensive activities of Tibolone.	Approved, Investigational
Ticrynafen	Lisinopril may increase the hypotensive activities of Ticrynafen.	Withdrawn
Timolol	Timolol may increase the hypotensive activities of Lisinopril.	Approved
Tinoridine	The risk or severity of adverse effects can be increased when Tinoridine is combined with Lisinopril.	Investigational
Tipranavir	The serum concentration of Lisinopril can be decreased when it is combined with Tipranavir.	Approved, Investigational
Tizanidine	Tizanidine may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Tolazoline	Lisinopril may increase the hypotensive activities of Tolazoline.	Approved, Vet Approved
Tolcapone	The risk or severity of adverse effects can be increased when Tolcapone is combined with Lisinopril.	Approved, Withdrawn
Tolfenamic Acid	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Lisinopril.	Approved, Investigational
Tolmetin	The risk or severity of adverse effects can be increased when Tolmetin is combined with Lisinopril.	Approved
Tolonidine	Lisinopril may increase the hypotensive activities of Tolonidine.	Experimental
Toloxatone	Toloxatone may increase the hypotensive activities of Lisinopril.	Approved
Tolvaptan	Tolvaptan may increase the hyperkalemic activities of Lisinopril.	Approved
Torasemide	Torasemide may increase the hypotensive activities of Lisinopril.	Approved
Trandolapril	Trandolapril may increase the hypotensive activities of Lisinopril.	Approved
Tranylcypromine	Tranylcypromine may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Travoprost	Travoprost may increase the hypotensive activities of Lisinopril.	Approved
Treprostinil	Treprostinil may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Tretinoin	The risk or severity of adverse effects can be increased when Tretinoin is combined with Lisinopril.	Approved, Investigational, Nutraceutical
Triamterene	Triamterene may increase the hyperkalemic activities of Lisinopril.	Approved
Triazolam	The serum concentration of Triazolam can be increased when it is combined with Lisinopril.	Approved, Investigational
Tribenoside	The risk or severity of adverse effects can be increased when Tribenoside is combined with Lisinopril.	Experimental
Trichlormethiazide	The risk or severity of hypotension can be increased when Trichlormethiazide is combined with Lisinopril.	Approved, Vet Approved
Trimazosin	Trimazosin may increase the hypotensive activities of Lisinopril.	Experimental
Trimethaphan	Trimethaphan may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Trimethoprim	Trimethoprim may increase the hyperkalemic activities of Lisinopril.	Approved, Vet Approved
Trimipramine	The serum concentration of Trimipramine can be increased when it is combined with Lisinopril.	Approved
Triptolide	The risk or severity of adverse effects can be increased when Triptolide is combined with Lisinopril.	Investigational
Trolamine salicylate	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Lisinopril.	Approved
Udenafil	Udenafil may increase the antihypertensive activities of Lisinopril.	Approved, Investigational
Unoprostone	Lisinopril may increase the hypotensive activities of Unoprostone.	Approved, Investigational
Urapidil	Urapidil may increase the hypotensive activities of Lisinopril.	Investigational
Valdecoxib	The risk or severity of adverse effects can be increased when Valdecoxib is combined with Lisinopril.	Approved, Investigational, Withdrawn
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Lisinopril.	Approved, Investigational
Vardenafil	Vardenafil may increase the antihypertensive activities of Lisinopril.	Approved
Verapamil	The risk or severity of adverse effects can be increased when Verapamil is combined with Lisinopril.	Approved
Vildagliptin	The risk or severity of adverse effects can be increased when Vildagliptin is combined with Lisinopril.	Approved, Investigational
Vincamine	Lisinopril may increase the hypotensive activities of Vincamine.	Experimental
Xipamide	Lisinopril may increase the hypotensive activities of Xipamide.	Experimental
Xylometazoline	Lisinopril may increase the hypotensive activities of Xylometazoline.	Approved, Investigational
Yohimbine	Yohimbine may decrease the antihypertensive activities of Lisinopril.	Approved, Investigational, Vet Approved
Zaltoprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Lisinopril.	Approved, Investigational
Zileuton	The risk or severity of adverse effects can be increased when Zileuton is combined with Lisinopril.	Approved, Investigational, Withdrawn
Zofenopril	Lisinopril may increase the hypotensive activities of Zofenopril.	Experimental
Zomepirac	The risk or severity of adverse effects can be increased when Zomepirac is combined with Lisinopril.	Withdrawn

Food Interactions

• Herbs that may attenuate the antihypertensive effect of lisinopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
• High salt intake may attenuate the antihypertensive effect of lisinopril.
• Lisinopril decreases the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia.
• Take without regard to meals.

References

Synthesis Reference

Vincenzo Cannata, Valeriano Merli, Stefano Saguatti, "Process for the production of alkoxycarbonyldipeptides intermediates in the synthesis of the lisinopril." U.S. Patent US6166217, issued September, 1972.

US6166217

General References

1. Abdelmalek MF, Douglas DD: Lisinopril-induced isolated visceral angioedema: review of ACE-inhibitor-induced small bowel angioedema. Dig Dis Sci. 1997 Apr;42(4):847-50. [PubMed:9125659]
2. Hasslacher C: Influence of the ACE inhibitor lisinopril on blood pressure, metabolism, and renal function parameter in hypertensive type II diabetic patients: a postmarketing surveillance study. J Diabetes Complications. 1996 May-Jun;10(3):136-8. [PubMed:8807458]
3. Nielsen SE, Sugaya T, Tarnow L, Lajer M, Schjoedt KJ, Astrup AS, Baba T, Parving HH, Rossing P: Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care. 2009 Sep;32(9):1684-8. doi: 10.2337/dc09-0429. Epub 2009 Jun 5. [PubMed:19502542]
4. Patchett AA, Harris E, Tristram EW, Wyvratt MJ, Wu MT, Taub D, Peterson ER, Ikeler TJ, ten Broeke J, Payne LG, Ondeyka DL, Thorsett ED, Greenlee WJ, Lohr NS, Hoffsommer RD, Joshua H, Ruyle WV, Rothrock JW, Aster SD, Maycock AL, Robinson FM, Hirschmann R, Sweet CS, Ulm EH, Gross DM, Vassil TC, Stone CA: A new class of angiotensin-converting enzyme inhibitors. Nature. 1980 Nov 20;288(5788):280-3. [PubMed:6253826]

External Links

Human Metabolome Database

HMDB0001938

KEGG Drug

D00362

PubChem Compound

5362119

PubChem Substance

46504893

ChemSpider

4514933

BindingDB

50367879

ChEBI

43755

ChEMBL

CHEMBL1237

Therapeutic Targets Database

DAP000587

PharmGKB

PA450242

HET

LPR

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

PDRhealth

PDRhealth Drug Page

Wikipedia

Lisinopril

ATC Codes

C09AA03 — Lisinopril

• C09AA — ACE inhibitors, plain
• C09A — ACE INHIBITORS, PLAIN
• C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
• C — CARDIOVASCULAR SYSTEM

C09BB03 — Lisinopril and amlodipine

• C09BB — ACE inhibitors and calcium channel blockers
• C09B — ACE INHIBITORS, COMBINATIONS
• C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
• C — CARDIOVASCULAR SYSTEM

C10BX07 — Rosuvastatin, amlodipine and lisinopril

• C10BX — HMG CoA reductase inhibitors, other combinations
• C10B — LIPID MODIFYING AGENTS, COMBINATIONS
• C10 — LIPID MODIFYING AGENTS
• C — CARDIOVASCULAR SYSTEM

C09BA03 — Lisinopril and diuretics

• C09BA — ACE inhibitors and diuretics
• C09B — ACE INHIBITORS, COMBINATIONS
• C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
• C — CARDIOVASCULAR SYSTEM

AHFS Codes

• 24:32.04 — Angiotensin-converting Enzyme Inhibitors

PDB Entries

1j36 / 1o86 / 2c6n / 2x91

FDA label

Download (267 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Healthy Volunteers	1
1	Completed	Not Available	To Determine Bioequivalence Under Fed Conditions	1
1	Completed	Not Available	Type 2 Diabetes Mellitus	1
1	Completed	Basic Science	Gastroparesis	1
1	Completed	Other	Healthy Volunteers	1
1	Completed	Prevention	High Blood Pressure (Hypertension)	1
1	Completed	Treatment	Diabetes Mellitus (DM) / Healthy Volunteers	2
1	Completed	Treatment	Fasting	2
1	Completed	Treatment	Fed	2
1	Completed	Treatment	High Blood Pressure (Hypertension)	5
1	Completed	Treatment	Strokes	1
1	Completed	Treatment	Type 2 Diabetes Mellitus	1
1	Recruiting	Treatment	Hypertension, Resistant to Conventional Therapy	1
1, 2	Completed	Treatment	Pre-Hypertension	1
2	Active Not Recruiting	Supportive Care	Cancer, Breast / Cardiac Toxicity	1
2	Completed	Treatment	Aging / Cognitive Impairments / High Blood Pressure (Hypertension)	1
2	Completed	Treatment	Glomerulosclerosis, Focal Segmental	1
2	Completed	Treatment	Hypertension,Essential	1
2	Completed	Treatment	Oligozoospermia	1
2	Not Yet Recruiting	Prevention	Pacemakers, Heart Failure	1
2	Not Yet Recruiting	Treatment	Albuminuria / Genetic Predisposition / Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) / Kidney Diseases	1
2	Recruiting	Treatment	Acute Coronary Syndromes (ACS) / Arterial Hypertension	1
2	Recruiting	Treatment	Extracapillary Glomerulonephritis	1
2	Terminated	Treatment	High Blood Pressure (Hypertension) / Unspecified Adult Solid Tumor, Protocol Specific	1
2, 3	Completed	Treatment	Becker's Muscular Dystrophy (BMD) / Duchenne's Muscular Dystrophy (DMD) / Limb Girdle Muscular Dystrophy	1
3	Active Not Recruiting	Prevention	High Blood Pressure (Hypertension) / Mild Cognitive Impairment (MCI)	1
3	Completed	Prevention	Atherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus	1
3	Completed	Prevention	Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Heart Diseases / Heart Failure, Unspecified / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Myocardial Infarction / Myocardial Ischemia	1
3	Completed	Prevention	Diabetic Nephropathies	1
3	Completed	Treatment	High Blood Pressure (Hypertension)	3
3	Completed	Treatment	High Blood Pressure (Hypertension) / Obesity, Abdominal	1
3	Completed	Treatment	Kidney, Polycystic	2
3	Completed	Treatment	Left Ventricular Hypertrophy	1
3	Terminated	Treatment	Heart Failure, Congestive and Microalbuminuria / High Blood Pressure (Hypertension) / Microalbuminuria	1
3	Terminated	Treatment	Hemodialysis-dependent patients / High Blood Pressure (Hypertension) / Left Ventricular Hypertrophy	1
3	Terminated	Treatment	Kidney Diseases / Renal Dysfunction / Type 2 Diabetes Mellitus	1
3	Unknown Status	Treatment	Cardiovascular Disease (CVD)	1
3	Withdrawn	Prevention	Hyperoxaluria	1
4	Completed	Prevention	Perioperative Hypertension	1
4	Completed	Treatment	Diabetic Nephropathies	1
4	Completed	Treatment	Diabetic Nephropathies / High Blood Pressure (Hypertension)	1
4	Completed	Treatment	Heart Failure, Unspecified / Ventricular Dysfunction, Left	1
4	Completed	Treatment	High Blood Pressure (Hypertension)	3
4	Completed	Treatment	High Blood Pressure (Hypertension) / Induction of intra-operative hypotension	1
4	Completed	Treatment	Human Immunodeficiency Virus (HIV)	1
4	Completed	Treatment	Stage 2 Diastolic Hypertension	1
4	Not Yet Recruiting	Prevention	Cardiomyopathy Due to Drug / Heart Failure, Systolic	1
4	Not Yet Recruiting	Treatment	High Blood Pressure (Hypertension)	1
4	Recruiting	Treatment	Cardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Hypertension,Essential / Strokes	1
4	Recruiting	Treatment	High Blood Pressure (Hypertension)	1
4	Recruiting	Treatment	Pediatric Hypertension	1
4	Recruiting	Treatment	Proteinuria / Renal Insufficiency,Chronic	1
4	Suspended	Prevention	Cardiovascular Disease (CVD) / Osteoarthritis (OA)	1
4	Terminated	Prevention	Neurological Dysphagia / Pneumonia	1
4	Unknown Status	Treatment	High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus	1
4	Unknown Status	Treatment	Hypertension,Essential / Secondary Hypertension	1
Not Available	Active Not Recruiting	Supportive Care	Dyspnea / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Small Cell Lung Cancer (SCLC)	1
Not Available	Active Not Recruiting	Treatment	High Blood Pressure (Hypertension)	1
Not Available	Completed	Not Available	Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / High Blood Pressure (Hypertension) / Myocardial Infarction	1
Not Available	Completed	Not Available	Diabetes Complications / Diabetes, Diabetes Mellitus Type 1 / Eye Diseases / Retinopathy, Diabetic	1
Not Available	Completed	Diagnostic	Arterial Hypertension	1
Not Available	Completed	Other	Hyperparathyroidism	1
Not Available	Completed	Prevention	Atherosclerosis / Cardiovascular Disease (CVD) / Cerebral Arteriosclerosis / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Heart Diseases / High Blood Pressure (Hypertension)	1
Not Available	Completed	Prevention	BMI >30 kg/m2 / Type 2 Diabetes Mellitus	1
Not Available	Completed	Prevention	Cardiovascular Disease Risk / Human Immunodeficiency Virus (HIV) Infections	1
Not Available	Completed	Prevention	Diabetes, Diabetes Mellitus Type 1 / Diabetic Nephropathies	1
Not Available	Completed	Treatment	BMI >30 kg/m2 / Pre-Diabetic	1
Not Available	Completed	Treatment	Cardiovascular Disease (CVD) / Cerebrovascular Diseases / Peripheral Arterial Disease (PAD)	1
Not Available	Completed	Treatment	Cardiovascular Disease (CVD) / Chronic Kidney Disease (CKD)	1
Not Available	Completed	Treatment	Duchenne's Muscular Dystrophy (DMD) / Prophylaxis of cardiomyopathy	1
Not Available	Completed	Treatment	High Blood Pressure (Hypertension) / Hypertension Treatment / Hypertension, Grade 1 / N of 1 Study Design	1
Not Available	Completed	Treatment	High Blood Pressure (Hypertension) / Plasma Renin Activity	1
Not Available	Completed	Treatment	Hypertension,Essential	1
Not Available	Terminated	Prevention	Thoracic Pain	1
Not Available	Terminated	Treatment	Type 2 Diabetes Mellitus	1
Not Available	Withdrawn	Treatment	Diastolic Heart Failure	1
Not Available	Withdrawn	Treatment	High Blood Pressure (Hypertension)	1

Pharmacoeconomics

Manufacturers

• Actavis elizabeth llc
• Apotex inc etobicoke site
• Aurobindo pharma ltd
• Ivax pharmaceuticals inc sub teva pharmaceuticals usa
• Lek pharmaceuticals d d
• Lupin ltd
• Mylan pharmaceuticals inc
• Ranbaxy pharmaceuticals inc
• Sandoz inc
• Teva pharmaceuticals usa inc
• Vintage pharmaceuticals llc
• Watson laboratories inc
• West ward pharmaceutical corp
• Wockhardt ltd
• Merck research laboratories div merck co inc
• Astrazeneca uk ltd

Packagers

• Advanced Pharmaceutical Services Inc.
• Aidarex Pharmacuticals LLC
• Amerisource Health Services Corp.
• Apotex Inc.
• Apotheca Inc.
• A-S Medication Solutions LLC
• AstraZeneca Inc.
• Aurobindo Pharma Ltd.
• Blu Pharmaceuticals LLC
• Bryant Ranch Prepack
• Cardinal Health
• Comprehensive Consultant Services Inc.
• Coupler Enterprises Inc.
• Dept Health Central Pharmacy
• DHHS Program Support Center Supply Service Center
• Direct Dispensing Inc.
• Dispensing Solutions
• Diversified Healthcare Services Inc.
• Eon Labs
• Golden State Medical Supply Inc.
• Greenstone LLC
• Group Health Cooperative
• H.J. Harkins Co. Inc.
• Heartland Repack Services LLC
• Innoviant Pharmacy Inc.
• International Laboratories Inc.
• IPR Pharmaceuticals Inc.
• Ivax Pharmaceuticals
• Kaiser Foundation Hospital
• Lake Erie Medical and Surgical Supply
• Lek Pharmaceuticals Inc.
• Liberty Pharmaceuticals
• Lupin Pharmaceuticals Inc.
• Major Pharmaceuticals
• Mckesson Corp.
• Medvantx Inc.
• Merck & Co.
• Murfreesboro Pharmaceutical Nursing Supply
• Mylan
• Neighborcare Repackaging Inc.
• Novartis AG
• Nucare Pharmaceuticals Inc.
• Ohm Laboratories Inc.
• Palmetto Pharmaceuticals Inc.
• PCA LLC
• PD-Rx Pharmaceuticals Inc.
• Pharmaceutical Utilization Management Program VA Inc.
• Physicians Total Care Inc.
• Preferred Pharmaceuticals Inc.
• Prepackage Specialists
• Prepak Systems Inc.
• Prescript Pharmaceuticals
• Professional Co.
• Promex Medical Inc.
• Qualitest
• Ranbaxy Laboratories
• Rebel Distributors Corp.
• Remedy Repack
• Resource Optimization and Innovation LLC
• Sandhills Packaging Inc.
• Sandoz
• Southwood Pharmaceuticals
• Stat Rx Usa
• Stat Scripts LLC
• Talbert Medical Management Corp.
• Teva Pharmaceutical Industries Ltd.
• Torpharm Inc.
• Tya Pharmaceuticals
• UDL Laboratories
• Va Cmop Dallas
• Vangard Labs Inc.
• Watson Pharmaceuticals
• West-Ward Pharmaceuticals
• Wockhardt Ltd.

Dosage forms

Form	Route	Strength
Tablet	Oral	40 mg
Tablet	Oral	5 mg
Tablet	Oral	10 mg/301
Tablet	Oral	10 mg/1
Tablet	Oral	10 1/1
Tablet	Oral	2.5 mg/1
Tablet	Oral	20 mg/1
Tablet	Oral	30 mg/1
Tablet	Oral	40 mg/1
Tablet	Oral	5 mg/1
Tablet, film coated	Oral	10 mg/1
Tablet, film coated	Oral	2.5 mg/1
Tablet, film coated	Oral	20 mg/1
Tablet, film coated	Oral	30 mg/1
Tablet, film coated	Oral	40 mg/1
Tablet, film coated	Oral	5 mg/1
Tablet	Oral
Kit
Tablet	Oral	10 mg
Tablet	Oral	2.5 mg
Tablet	Oral	20 mg
Solution	Oral	1 mg/mL

Prices

Unit description	Cost	Unit
Prinivil 90 20 mg tablet Bottle	111.71USD	bottle
Prinzide 30 20-12.5 mg tablet Bottle	45.99USD	bottle
Prinivil 30 2.5 mg tablet Bottle	22.48USD	bottle
Lisinopril 100% powder	21.6USD	g
Zestril 40 mg tablet	2.53USD	tablet
Zestril 30 mg tablet	2.41USD	tablet
Prinivil 40 mg tablet	2.23USD	tablet
Zestoretic 20-25 mg tablet	2.01USD	tablet
Zestoretic 20-12.5 mg tablet	2.0USD	tablet
Prinzide 20-25 mg tablet	1.98USD	tablet
Zestoretic 10-12.5 mg tablet	1.89USD	tablet
Zestoretic 10-12.5 tablet	1.75USD	tablet
Lisinopril 30 mg tablet	1.53USD	tablet
Lisinopril 40 mg tablet	1.44USD	tablet
Prinzide 20-12.5 mg tablet	1.38USD	tablet
Prinzide 10-12.5 mg tablet	1.37USD	tablet
Zestril 20 mg tablet	1.37USD	tablet
Zestril 10 mg tablet	1.33USD	tablet
Zestoretic 20-25 tablet	1.28USD	tablet
Zestril 5 mg tablet	1.28USD	tablet
Zestoretic 20-12.5 tablet	1.26USD	tablet
Lisinopril 20 mg tablet	1.09USD	tablet
Prinivil 20 mg tablet	1.05USD	tablet
Zestril 2.5 mg tablet	1.04USD	tablet
Lisinopril 10 mg tablet	1.01USD	tablet
Prinivil 10 mg tablet	1.01USD	tablet
Lisinopril 5 mg tablet	0.99USD	tablet
Prinivil 5 mg tablet	0.96USD	tablet
Apo-Lisinopril 20 mg Tablet	0.71USD	tablet
Co Lisinopril 20 mg Tablet	0.71USD	tablet
Mylan-Lisinopril 20 mg Tablet	0.71USD	tablet
Novo-Lisinopril (Type P) 20 mg Tablet	0.71USD	tablet
Novo-Lisinopril (Type Z) 20 mg Tablet	0.71USD	tablet
Pms-Lisinopril 20 mg Tablet	0.71USD	tablet
Ran-Lisinopril 20 mg Tablet	0.71USD	tablet
Ratio-Lisinopril P 20 mg Tablet	0.71USD	tablet
Ratio-Lisinopril Z 20 mg Tablet	0.71USD	tablet
Sandoz Lisinopril 20 mg Tablet	0.71USD	tablet
Lisinopril 2.5 mg tablet	0.65USD	tablet
Apo-Lisinopril 10 mg Tablet	0.59USD	tablet
Co Lisinopril 10 mg Tablet	0.59USD	tablet
Mylan-Lisinopril 10 mg Tablet	0.59USD	tablet
Novo-Lisinopril (Type P) 10 mg Tablet	0.59USD	tablet
Novo-Lisinopril (Type Z) 10 mg Tablet	0.59USD	tablet
Pms-Lisinopril 10 mg Tablet	0.59USD	tablet
Ran-Lisinopril 10 mg Tablet	0.59USD	tablet
Ratio-Lisinopril P 10 mg Tablet	0.59USD	tablet
Ratio-Lisinopril Z 10 mg Tablet	0.59USD	tablet
Sandoz Lisinopril 10 mg Tablet	0.59USD	tablet
Apo-Lisinopril 5 mg Tablet	0.49USD	tablet
Co Lisinopril 5 mg Tablet	0.49USD	tablet
Mylan-Lisinopril 5 mg Tablet	0.49USD	tablet
Novo-Lisinopril (Type P) 5 mg Tablet	0.49USD	tablet
Novo-Lisinopril (Type Z) 5 mg Tablet	0.49USD	tablet
Pms-Lisinopril 5 mg Tablet	0.49USD	tablet
Ran-Lisinopril 5 mg Tablet	0.49USD	tablet
Ratio-Lisinopril P 5 mg Tablet	0.49USD	tablet
Ratio-Lisinopril Z 5 mg Tablet	0.49USD	tablet
Sandoz Lisinopril 5 mg Tablet	0.49USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US9463183	No	2015-11-06	2035-11-06
US9616096	No	2015-11-06	2035-11-06
US9814751	No	2015-11-06	2035-11-06

Properties

State

Solid

Experimental Properties

Property	Value	Source
water solubility	9.7E+004 mg/L	MERCK INDEX (1996)
logP	-1.01	MERCK INDEX (1996); pH 7
pKa	2.5 (at 25 °C)	MERCK INDEX (1996)

Predicted Properties

Property	Value	Source
Water Solubility	0.216 mg/mL	ALOGPS
logP	-1.2	ALOGPS
logP	-3.1	ChemAxon
logS	-3.3	ALOGPS
pKa (Strongest Acidic)	3.17	ChemAxon
pKa (Strongest Basic)	10.21	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	7	ChemAxon
Hydrogen Donor Count	4	ChemAxon
Polar Surface Area	132.96 Å2	ChemAxon
Rotatable Bond Count	12	ChemAxon
Refractivity	107.37 m3·mol-1	ChemAxon
Polarizability	43.5 Å3	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.6426
Blood Brain Barrier	-	0.8815
Caco-2 permeable	-	0.7605
P-glycoprotein substrate	Substrate	0.6515
P-glycoprotein inhibitor I	Non-inhibitor	0.9512
P-glycoprotein inhibitor II	Non-inhibitor	0.969
Renal organic cation transporter	Non-inhibitor	0.8574
CYP450 2C9 substrate	Non-substrate	0.8793
CYP450 2D6 substrate	Non-substrate	0.7622
CYP450 3A4 substrate	Non-substrate	0.725
CYP450 1A2 substrate	Non-inhibitor	0.8999
CYP450 2C9 inhibitor	Non-inhibitor	0.9708
CYP450 2D6 inhibitor	Non-inhibitor	0.9653
CYP450 2C19 inhibitor	Non-inhibitor	0.8266
CYP450 3A4 inhibitor	Non-inhibitor	0.907
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9821
Ames test	Non AMES toxic	0.9133
Carcinogenicity	Non-carcinogens	0.9389
Biodegradation	Not ready biodegradable	0.6844
Rat acute toxicity	1.8723 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9641
hERG inhibition (predictor II)	Non-inhibitor	0.8708

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
MS/MS Spectrum - Quattro_QQQ 10V, Positive	LC-MS/MS	splash10-0a4r-0194100000-d9a47a283478b88bb101
MS/MS Spectrum - Quattro_QQQ 25V, Positive	LC-MS/MS	splash10-001i-9040000000-8d6d4ae6ba18da11e336
MS/MS Spectrum - Quattro_QQQ 40V, Positive	LC-MS/MS	splash10-001i-9000000000-77e20f7eb799eea58ab0
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
1H NMR Spectrum	1D NMR	Not Applicable
[1H,13C] 2D NMR Spectrum	2D NMR	Not Applicable

Taxonomy

Description

This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Carboxylic acids and derivatives

Sub Class

Amino acids, peptides, and analogues

Direct Parent

Dipeptides

Alternative Parents

Proline and derivatives / N-acyl-L-alpha-amino acids / Alpha amino acid amides / L-alpha-amino acids / Pyrrolidine carboxylic acids / N-acylpyrrolidines / Aralkylamines / Benzene and substituted derivatives / Dicarboxylic acids and derivatives / Tertiary carboxylic acid amidesAmino acids / Dialkylamines / Carboxylic acids / Azacyclic compounds / Hydrocarbon derivatives / Carbonyl compounds / Organopnictogen compounds / Organic oxides / Monoalkylamines

show 9 more

Substituents

Alpha-dipeptide / N-acyl-alpha-amino acid / Proline or derivatives / N-acyl-alpha amino acid or derivatives / N-acyl-l-alpha-amino acid / Alpha-amino acid amide / Alpha-amino acid / Alpha-amino acid or derivatives / L-alpha-amino acid / N-acylpyrrolidinePyrrolidine carboxylic acid / Pyrrolidine carboxylic acid or derivatives / Aralkylamine / Benzenoid / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Tertiary carboxylic acid amide / Pyrrolidine / Amino acid or derivatives / Carboxamide group / Amino acid / Organoheterocyclic compound / Secondary amine / Azacycle / Carboxylic acid / Secondary aliphatic amine / Hydrocarbon derivative / Primary aliphatic amine / Organic oxide / Organic nitrogen compound / Organonitrogen compound / Carbonyl group / Organooxygen compound / Primary amine / Amine / Organic oxygen compound / Organopnictogen compound / Aromatic heteromonocyclic compound

show 28 more

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

dipeptide (CHEBI:43755)

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:44